Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.58 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylose SCHEMBL23925306 | 1.00 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL20423632 | 0.99 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL28724079 | 0.99 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Demannose SCHEMBL27666893 | 0.96 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL23706155 | 0.95 | F7 (0.52) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL28825332 | 0.94 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL28825318 | 0.94 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL4484244 | 0.91 | SIRT2 (0.48) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL28724080 | 0.90 | F7 (0.47) | F7F3SARM1SIRT2SIRT6 | |
| Mannitol SCHEMBL9807801 | 0.89 | F7 (0.69) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 878 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2026-03-19 | — | — | US | claimed |
| EP-4683625-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | The Trustees Of Columbia University In The City Of New York (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250381177-A1 | TREATMENT AND PREVENTION OF OCULAR NEURODEGENERATIVE DISORDER | JACKSON LAB (US) | 2025-12-18 | — | — | US | claimed |
| US-20250312286-A1 | METHOD FOR PREPARING MICROCAPSULE, MICROCAPSULE AND COMPOSITION CONTAINING THE SAME | XIAMEN KINGDOMWAY BIOTECH. CO., LTD. (CN) | 2025-10-09 | — | — | US | claimed |
| US-12336986-B2 | Treatment and prevention of ocular neurodegenerative disorder | THE JACKSON LABORATORY (US) | 2025-06-24 | — | — | US | claimed |
| CN-119931825-A | Preparation device and preparation method for nicotinamide ribose by using biological enzyme method | 安徽瑞邦生物科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119656631-B | Purification device and purification method for nicotinamide riboside | 安徽瑞邦生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119792333-A | Lipid nanoparticle and synthesis method thereof | 罗恩丽 | 2025-04-11 | — | — | CN | claimed |
| CN-119776463-A | Process for producing nicotinamide riboside by high-density fermentation | 江西海文生物科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119656631-A | Purification device and purification method for nicotinamide riboside | 安徽瑞邦生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-3364973-A1 | NICOTINAMIDE FOR USE IN THE TREATMENT AND PREVENTION OF OCULAR NEURODEGENERATIVE DISORDER (E.G. GLAUCOMA) | The Jackson Laboratory (US) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070647-A1 | NICOTINAMIDE FOR USE IN THE TREATMENT AND PREVENTION OF OCULAR NEURODEGENERATIVE DISORDER (E.G. GLAUCOMA) | THE JACKSON LABORATORY (US) | 2017-04-27 | — | — | WO | claimed |
| US-9597271-B2 | Cosmetic compositions and methods | THE PROCTER & GAMBLE COMPANY (US) | 2017-03-21 | — | — | US | claimed |
| EP-3060311-A1 | SKIN LIGHTENING COSMETIC COMPOSITIONS AND METHODS | The Procter & Gamble Company (US) | 2016-08-31 | — | — | EP | claimed |
| WO-2015061512-A1 | SKIN LIGHTENING COSMETIC COMPOSITIONS AND METHODS | THE PROCTER & GAMBLE COMPANY (US) | 2015-04-30 | — | — | WO | claimed |
| US-20150118169-A1 | COSMETIC COMPOSITIONS AND METHODS | THE PROCTER & GAMBLE COMPANY | 2015-04-30 | — | — | US | claimed |
| US-20130165398-A1 | CONCENTRATION-ENHANCING DRINK | HOCHEGGER, PAUL (AT) | 2013-06-27 | — | — | US | claimed |
| EP-2464249-B1 | CONCENTRATION-ENHANCING DRINK | HUBER JOHANNES (AT) | 2013-03-13 | — | — | EP | claimed |
| EP-0918789-A1 | PYRIDINE NUCLEOTIDE-DEPENDENT ENZYMES | THE UNIVERSITY OF SHEFFIELD (GB) | 1999-06-02 | — | — | EP | claimed |
| WO-1997048722-A1 | PYRIDINE NUCLEOTIDE-DEPENDENT ENZYMES | THE UNIVERSITY OF SHEFFIELD (GB) | 1997-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | PC, PDK1, PDK4 | F7 3731/4885F3 1716/4885SARM1 930/4885 |
| US-20150118169-A1 | COSMETIC COMPOSITIONS AND METHODS | PSMB4, CTRB1, SERPINB6 | F7 3253/4885F3 1841/4885SARM1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.